Table 1.
Participant demographics and clinical features.
| VBM study |
fMRI experiment |
|||
|---|---|---|---|---|
| ALS patients | Healthy controls | ALS patients | Healthy controls | |
| Gender (M/F) | 13/13 | 13/15 | 13/1 | 13/1 |
| Age (years) | 60.4 ± 2.2a,c (30-86) | 60.1 ± 1.9a,d (33-78) | 60.3 ± 3.1b,c (39-76) | 59.7 ± 3.3b,d (42-79) |
| Disease duration (months) | 23.8 ± 4.8(6–120) | NA | 18.3 ± 3.1 (6-49) | NA |
| Site of onset (spinal/bulbar) | 22/4 | NA | 11/3 | NA |
| ALSFRS-R | 36.2 ± 1.2(20-46) | NA | 38.2 ± 1.3 (26-44) | NA |
| MRC-Megascore | NA | NA | 130.9 ± 5.1 (79-150) | NA |
| Rate of disease-progression | 0.74 ± 0.09 (0.13–2.0) | NA | 0.66 ± 0.09 (0.22–1.5) | NA |
Data for the subjects' age, disease duration, ALSFRS-R, MRC-Megascore, and the rate of disease-progression are presented as mean ± standard error of the mean. Abbreviations: ALSFRS-R, revised ALS Functional Rating Scale; MRC, Medical Research Council.
Two-sample t-tests
a
T(1,52) = 0.08, p > 0.9;
b
T(1,26) = 1.45, p > 0.1;
c
T(1,38) = 0.02, p > 0.9;
d
T(1,40) = 1.79, p > 0.1.